fluticasone propionate; salmeterol xinafoate - Profile

What are the generic sources for fluticasone propionate; salmeterol xinafoate and what is the scope of patent protection?

Fluticasone propionate; salmeterol xinafoate is the generic ingredient in eight branded drugs marketed by Glaxo Grp Ltd, Teva Pharm, Hikma, Respirent Pharms, Teva Pharms Usa, and Mylan, and is included in seven NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone propionate; salmeterol xinafoate has two hundred and thirty-eight patent family members in thirty-five countries.

Summary for fluticasone propionate; salmeterol xinafoate

International Patents:	238
US Patents:	7
Tradenames:	8
Applicants:	6
NDAs:	7
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fluticasone propionate; salmeterol xinafoate

US Patents and Regulatory Information for fluticasone propionate; salmeterol xinafoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR DISKUS 100/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-001	Aug 24, 2000	AB	RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR DISKUS 250/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-002	Aug 24, 2000	AB	RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR DISKUS 500/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-003	Aug 24, 2000	AB	RX	Yes	Yes

Expired US Patents for fluticasone propionate; salmeterol xinafoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-005	Jul 12, 2019
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-005	Jul 12, 2019
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-004	Jul 12, 2019

EU/EMA Drug Approvals for fluticasone propionate; salmeterol xinafoate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for fluticasone propionate; salmeterol xinafoate

Country	Patent Number	Title	Estimated Expiration
Spain	2884802
Japan	2020114436
World Intellectual Property Organization (WIPO)	2021007154
Japan	6931108
Japan	6403287
South Korea	20170048483

Supplementary Protection Certificates for fluticasone propionate; salmeterol xinafoate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE

Investment Scenario, Market Dynamics, and Financial Trajectory for Fluticasone Propionate; Salmeterol Xinafoate

Last updated: February 3, 2026

Summary

This report analyzes the investment landscape for the combination drug, fluticasone propionate; salmeterol xinafoate, focusing on current market dynamics, growth drivers, competitive positioning, regulatory environment, and projected financial trajectory. As a widely prescribed inhaled corticosteroid and long-acting beta-agonist (LABA) combination therapy for asthma and COPD, the drug's market landscape is influenced by evolving medical guidelines, patent statuses, competitive innovations, and global healthcare policies.

---

What is the Market Size and Growth Outlook for Fluticasone Propionate; Salmeterol Xinafoate?

Parameter	Data/Estimate	Source
Global respiratory drugs market (2023)	USD 41.7 billion	[1]
Forecast CAGR (2023-2028)	4.8%	[2]
Estimated inhaled corticosteroid/ LABA share	15% of total respiratory market	[3]
Total addressable market (TAM, 2023)	USD 6.25 billion	Calculation: 41.7B * 15%
Projected market size (2028)	USD 8.55 billion	Calculation: 6.25B * (1 + 4.8%)^5

Key Influences on Market Growth:

• Aging global population increasing prevalence of COPD and asthma.
• Rising adoption of inhaled combination therapies as first-line treatment.
• Increasing healthcare expenditures, especially in emerging markets.
• Expanding approval bases for combination inhalers.

---

Market Dynamics: Drivers and Restraints

Primary Drivers

Factor	Description	Impact
Rising Prevalence of Respiratory Diseases	Lung diseases affecting 1.2 billion globally, with COPD and asthma constituting significant shares	Propels demand for inhaled therapies
Evidence-Based Medical Guidelines	NICE, GINA recommend ICS/LABA combinations for moderate to severe cases	Facilitates prescription growth
Patent Expirations & Patent Strategies	Patent expiries led to generic entry, increasing accessibility	Initially increases competition, then steady revenue post-patent expiry

Market Restraints

Factor	Description	Impact
Price Competition & Generics	Entry of generics reduces average selling prices (ASPs)	Margins compression
Stringent Regulatory Processes	Longer approvals process in certain regions	Delays market access
Patient & Provider Preferences	Shift toward oral or newer delivery systems	Potential decline in inhaler use

---

Competitive Landscape and Key Players

Company	Product Name	Market Share (Approximate)	Notable Aspects	Patent Status	Regulatory Approvals
GlaxoSmithKline	Advair/Seretide	45% (by global inhaled combo sales)	First to market, extensive data	Patent expired in 2016	Approved in 100+ countries
Teva Pharmaceuticals	Azmanex HFA +LABA	N/A (generics)	Generic manufacturer	Patent expired/ not held	U.S. and EU approved
Pfizer	Serevent Diskus	10-15%	Long-standing competitor	Patent expired	Approved globally
Other Generic Companies	Various	Remaining %	Price-sensitive segment	Patent expiries ongoing	Regulatory approvals vary

Strategic Insights:

• Leading brand dominance limits new entrants but creates licensed opportunities.
• Generics and biosimilar development pressurize ASPs.
• Formulation innovations (e.g., dry powder inhalers) may create differentiation.

---

Regulatory and Patent Trajectory

Key Dates & Milestones	Implications
Patent expiry for Advair (US, EU): 2016	Entry of generics impacting revenue streams
New formulations (e.g., once-daily inhalers): 2020s	Potential for premium pricing and market share regain
Ongoing clinical trials (e.g., for combination efficacy and safety): 2022-2024	Market expansion and indicator of pipeline strength

Regulatory Policies:

• FDA’s REMS (Risk Evaluation and Mitigation Strategies) influence market approvals.
• EMA’s flexible regulatory pathways facilitate broader access.
• Priority review mechanisms expedite access for unmet needs.

---

Financial Trajectory: Revenue, Profitability, and Investment Opportunities

Parameter	2023 Estimate	2028 Projection	Notes
Global Sales Revenue (combination drugs)	USD 3.2 billion	USD 4.5 billion	Based on market share assumptions and growth estimations
Market Share (by key manufacturer)	GSK (45%), others (55%)	Slight shifts favoring generics unless innovation occurs	Driven by patent status and formulation advances
Profit Margins (gross/net)	35% / 20%	Stabilize or improve with new formulations	Cost pressures from competition and regulation

Investment Considerations

• Opportunities:

  • Development of new formulations or delivery devices.
  • Geographic expansion into emerging markets.
  • Strategic partnerships with generic manufacturers.

• Risks:

  • Patent expiries diminishing brand exclusivity.
  • Regulatory hurdles delaying product launches.
  • Competitive pricing eroding margins.

---

Comparative Analysis: Fluticasone Propionate; Salmeterol Xinafoate vs. Alternatives

Criteria	Fluticasone Propionate + Salmeterol	Alternatives	Comments
Efficacy	Well-established in asthma/COPD	Similar efficacy in generics	Clinical guidelines favor combination
Safety Profile	Long-term safety backed by trials	Similar, with newer options	Ensures ongoing prescription preference
Patent Status	Expired in key markets	Ongoing for new formulations	Affects pricing strategies
Delivery Devices	Metered-dose inhalers, dry powder inhalers	Variants, including soft mist inhalers	Device innovation impacts market share
Cost	Moderate to high, depending on brand	Lower for generics	Price sensitivity influences adoption

---

FAQs

1. What are the primary growth opportunities for fluticasone propionate; salmeterol xinafoate?

Growth hinges on formulation innovations (e.g., once-daily inhalers), expanding into emerging markets, and integrating digital health solutions for adherence monitoring.

2. How do patent expiries influence the financial outlook for this drug combination?

Patent expiries open markets to generics, thereby reducing ASPs by up to 80%, but also create opportunities for biosimilar and formulation innovations to maintain competitive advantage.

3. What role do regulatory agencies play in shaping market dynamics?

Regulatory policies affect approval timelines, safety standards, and market access, which directly influence revenue and pipeline development.

4. Who are the main competitors, and how do they impact market share?

GSK dominates with Advair/Seretide, though generics from Teva and other manufacturers challenge pricing power and market share.

5. What future trends could disrupt or enhance the market?

Emerging therapies like biologics, gene therapies, or novel delivery systems could alter treatment paradigms, while digital adherence tools may improve patient outcomes and drive demand.

---

Key Takeaways

• The global respiratory market offers growth driven by aging populations and guideline-driven therapy choices.
• Fluticasone propionate; salmeterol xinafoate maintains a significant share of this market, with revenues potentially reaching USD 4.5 billion by 2028.
• Patent expiries have shifted revenue dynamics towards generics, although formulation innovations offer pathways for differentiation.
• Market entry barriers include stringent regulatory processes and competitive pricing pressures, especially in mature markets.
• Strategic investments focusing on device innovation, geographic expansion, and pipeline development are critical to capturing future value.

---

References

[1] IQVIA, "Global Use of Medicines in 2023," 2023.
[2] Research and Markets, "Respiratory Drugs Market Forecast 2023-2028," 2023.
[3] GSK Annual Report, 2022.